• Corticosteroid-responsive disorders

Rayos Generic Name & Formulations

General Description

Prednisone 1mg, 2mg, 5mg; delayed-release tablets.

Pharmacological Class


How Supplied

Tabs—30, 100


Rayos Indications


Corticosteroid-responsive disorders.

Rayos Dosage and Administration

Adults and Children

See full labeling. Swallow whole with food. Individualize. The timing of administration should take into account the delayed-release pharmacokinetics (approximately 4-hour lag time from that of immediate-release prednisone) and the disease or condition being treated. Use lowest effective dose. Initially 5–60mg day. Conversion from immediate-release prednisone, prednisolone, or methylprednisolone: give equivalent dose based on relative potency.

Rayos Contraindications

Not Applicable

Rayos Boxed Warnings

Not Applicable

Rayos Warnings/Precautions


For prednisone in general: Systemic fungal infections, cerebral malaria, optic neuritis: not recommended. Tuberculosis. Latent amebiasis. Strongyloides infestation. Ocular herpes simplex. May increase risk and mask signs of infection. If exposed to chickenpox or measles, consider prophylactic passive immune therapy. HPA axis suppression. Cushing’s syndrome. Hyperglycemia. Thyroid disorders. Hypertension. CHF. Renal insufficiency. Recent MI. Risk of GI perforation. Peptic ulcer. Diverticulitis. Intestinal anastomoses. Myasthenia gravis. Osteoporosis. Kaposi’s sarcoma. May cause electrolyte imbalances or psychotic manifestations. Avoid abrupt cessation. Monitor weight, growth, BP, IOP, fluid and electrolyte balance. Elderly. Embryo-fetal toxicity (esp. during 1st trimester). Pregnancy: monitor neonates. Nursing mothers.

Rayos Pharmacokinetics

See Literature

Rayos Interactions


See Contraindications. Potentiated by CYP3A4 inhibitors (eg, ketoconazole, macrolides), cyclosporine, estrogens. Antagonized by CYP3A4 inducers (eg, barbiturates, phenytoin, carbamazepine, rifampin), cholestyramine, aminoglutethimide. May potentiate cyclosporine. May antagonize anticoagulants (monitor), isoniazid. Increased risk of arrhythmias with digitalis. May need to adjust dose of antidiabetic agents. Increased GI effects with aspirin or NSAIDs. Caution with aspirin in hypoprothrombinemia. Monitor for hypokalemia with potassium-depleting drugs. Withdraw anticholinesterase agents at least 24hrs before initiating therapy. May suppress reactions to skin tests.

Rayos Adverse Reactions

Adverse Reactions

Fluid retention, alteration in glucose tolerance, BP elevation, behavioral/mood changes, increased appetite, weight gain.

Rayos Clinical Trials

See Literature

Rayos Note

Not Applicable

Rayos Patient Counseling

See Literature